Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7RU1

SARS-CoV-2-6P-Mut7 S protein (C3 symmetry)

Summary for 7RU1
Entry DOI10.2210/pdb7ru1/pdb
EMDB information24693
DescriptorSpike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
Functional Keywordscovid, sars-cov-2, stabilizing mutations, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
Total number of polymer chains3
Total formula weight435714.13
Authors
Ozorowski, G.,Turner, H.L.,Ward, A.B. (deposition date: 2021-08-16, release date: 2022-08-24, Last modification date: 2024-11-13)
Primary citationZhao, F.,Keating, C.,Ozorowski, G.,Shaabani, N.,Francino-Urdaniz, I.M.,Barman, S.,Limbo, O.,Burns, A.,Zhou, P.,Ricciardi, M.J.,Woehl, J.,Tran, Q.,Turner, H.L.,Peng, L.,Huang, D.,Nemazee, D.,Andrabi, R.,Sok, D.,Teijaro, J.R.,Whitehead, T.A.,Ward, A.B.,Burton, D.R.,Jardine, J.G.
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways.
Iscience, 25:104914-104914, 2022
Cited by
PubMed Abstract: The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and prevent viral neutralization. Here, we used a directed evolution-based approach to engineer three neutralizing antibodies for enhanced binding to S protein. The engineered antibodies showed increased functional activity in terms of neutralization potency and/or breadth of neutralization against viral variants. Deep mutational scanning revealed that higher binding affinity reduces the total number of viral escape mutations. Studies in the Syrian hamster model showed two examples where the affinity-matured antibody provided superior protection compared to the parental antibody. These data suggest that monoclonal antibodies for antiviral indications would benefit from affinity maturation to reduce viral escape pathways and appropriate affinity maturation in vaccine immunization could help resist viral variation.
PubMed: 35971553
DOI: 10.1016/j.isci.2022.104914
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.8 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon